Skip to main content
. 2020 Jan 1;11(4):906–918. doi: 10.7150/jca.33766

Table 5.

Joint effects analysis between 4 protein and AFP with 2-year, 5-year and overall survival.

Variables Number
(n=389)a
2-year OS
p-valueb
2-year OS
HR(95% CI) b
5-year OS
p-valueb
5-year OS
HR(95% CI) b
Overall survival
p-valueb
Overall survival
HR(95% CI) b
p53/AFP
+/high 113 0.222 0.298 0.343
-/low 92 0.438 0.812(0.480-1.374) 0.203 0.750(0.481-1.169) 0.248 0.777(0.506-1.192)
+/low 122 0.038 0.584(0.352-0.969) 0.110 0.724(0.487-1.075) 0.249 0.804(0.554-1.165)
-/high 62 0.345 0.760(0.429-1.345) 0.147 0.693(0.423-1.137) 0.097 0.668(0.415-1.075)
p21/AFP
+/high 52 0.504 0.701 0.859
-/low 164 0.294 0.734(0.411-1.309) 0.524 0.857(0.534-1.376) 0.833 0.952(0.604-1.501)
+/low 50 0.530 0.790(0.378-1.650) 0.463 0.803(0.446-1.444) 0.902 1.034(0.603-1.774)
-/high 123 0.958 1.015(0.575-1.794) 0.911 1.028(0.638-1.656) 0.635 1.118(0.706-1.770)
nm23/AFP
+/high 159 0.424 0.647 0.883
-/low 23 0.373 0.581(0.176-1.917) 0.917 0.962(0.466-1.986) 0.908 1.040(0.535-2.023)
+/low 191 0.205 0.769(0.513-1.154) 0.271 0.827(0.590-1.160) 0.536 0.903(0.655-1.246)
-/high 16 0.600 1.258(0.533-2.971) 0.708 1.145(0.563-2.330) 0.770 1.106(0.563-2.171)
VEGF/AFP
+/high 137 0.100 0.197 0.130
-/low 55 0.027 0.444(0.217-0.910) 0.133 0.672(0.400-1.129) 0.291 0.778(0.489-1.239)
+/low 38 0.164 0.605(0.298-1.228) 0.094 0.598(0.328-1.092) 0.026 0.518(0.291-0.923)
-/high 159 0.201 0.756(0.493-1.161) 0.155 0.772(0.540-1.103) 0.182 0.792(0.562-1.115)

Notes: a information regarding AFP level was unavailable for 30 patients (n=389); HR, hazard ratio; CI, confidence interval. b Adjusted for drinking status, BCLC stages, PVTT ,radical hepatic resection and adjuvant antiviral treatment. OS, overall survival; HR, hazard ratio; CI, confidence interval; NA, not available.